Previous 10 | Next 10 |
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2021 financial results on Tuesday, April 27, 2021. AtriCure will host a confer...
The following slide deck was published by AtriCure, Inc. in conjunction with this event. For further details see: AtriCure (ATRC)Presents At Oppenheimer 31st Annual Healthcare Conference - Slideshow
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Oppenheimer 31 st Annual Healthcare Conference. A...
Image source: The Motley Fool. AtriCure Inc (NASDAQ: ATRC) Q4 2020 Earnings Call Feb 23, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: AtriCure Inc (ATRC) Q4 2020 Earnings Call Transcript
AtriCure, Inc. (ATRC) Q4 2020 Earnings Conference Call February 23, 2021 16:30 ET Company Participants Lynn Lewis - Gilmartin Group Mike Carrel - President & Chief Executive Officer Angie Wirick - Chief Financial Officer Conference Call Participants Mike Matson - Needham & Company Mat...
AtriCure (ATRC): Q4 Non-GAAP EPS of -$0.18 beats by $0.07; GAAP EPS of -$0.42 misses by $0.13.Revenue of $57.73M (-5.9% Y/Y) misses by $0.23M.Shares -5.03%.Press Release For further details see: AtriCure EPS beats by $0.07, misses on revenue
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter 2020 and full year 2020 financial results. “Despite challenges posed in 2020 as a result of the...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming SVB Leerink 10 th Annual Global Healthcare Conference...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2020 financial results on Tuesday, February 23, 2021. AtriCure ...
AtriCure ([[ATRC]] +0.8%) expects Q4 revenue to decline ~6% Y/Y and ~+5% M/M to ~$57.7M vs. consensus of $58.11M. FY2020 to drop ~11% Y/Y to $206.5M vs. consensus of $206.97M, impacted by the global decline in surgical procedures as a result of the COVID-19 pandemic. “We are pleased wi...
News, Short Squeeze, Breakout and More Instantly...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory approval from the National Medical Products A...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2024 financial results on Tuesday, Ju...